AUS
NZ
UK
CA
USA
IND
Source: janews, Shutterstock
Summary
- Three FTSE 250 index stocks have given over 25 per cent return on investment in the last one year.
- Dechra Pharmaceuticals gave 25.16 per cent, Genus Plc 54.21 per cent, and PureTech Health 25.69 per cent in a year.
For the FTSE 250 index, 2021 began on a good note as it added around a percent on the first day of the year. But investor sentiments do not seem to have returned completely, as the index opened trading on Friday, 26 February down 0.44 percent. Investors seem to be still cautious of the uncertainties pertaining to the Covid-19 situation.
At the same time, the optimism around a successful vaccination drive is seen among several companies on the index trading either like the pre-Coronavirus crash levels or above that.
Copyright © 2021 Kalkine Media Pty Ltd.
Here are three FTSE 250 healthcare stocks that have given over 25 per cent return in the last one year:
Dechra Pharmaceuticals Plc (LON: DPH)
The UK-based company, involved in the veterinary business, has given 25.16 per cent one-year return on investment in 2020. This week, the company announced that both group revenues and operating profits of the company had increased through the last six months, ended 31 December 2020.
In fact, the company’s group revenues increased by 21.8 per cent while its operating profits were up by 74.2 per cent due to its strong trading performance.
Also read: Two FTSE Listed Healthcare Stocks in Limelight - Hikma Pharmaceuticals & Dechra Pharmaceuticals
Dechra CEO Ian Page said that though the year 2020 was one of the most difficult years in the company’s history, but the company managed to perform excellently well during the year.
It also recently announced that it secured the rights to exclusively sell and market animal pain management medicine Tri-Solfen in Australia and New Zealand.
Genus Plc (LON:GNS)
For the year 2020, the company’s one-year return on investment was 54.21 per cent for 2020. On Thursday, Genus posted its results, where it said that it has generated £285.7 million revenue for six months ended 31 December 2020. Its revenue rose 6 per cent from £270.7 million in 2019.
The company’s pre-tax profit for the same period was £38.7 million, an increase of 27 per cent from £30.4 million in 2019.
Also read: Performance Review of Two FTSE Listed Healthcare Stocks: Genus PLC & Indivior PLC
CEO Stephan Wilson said that the company managed to grow despite the challenging times and China, Brazil, India, and Russia have been high growth markets. The expansion of porcine genetics in China also added to the company’s performance. He also said Europe growth too was robust.
PureTech Heath Plc (LON:PRTC)
The UK-based biotechnology company has given a one-year return on investment of 25.69 per cent for 2020. The company recently announced that it had sold 1 million shares of its founded company Karuna Therapeutics through block trade for about $118 million.
The company said it would be using the money for the expansion and development of its wholly owned clinical-stage pipeline.
